Sarepta Therapeutics (LTS:0L35) Short Interest


LTS:0L35 Sarepta Therapeutics Inc LTS:0L35
51 GF Score
Price $16.10
GF Value $128.15
Valuation Possible Value Trap
! 5 Warning Signs
View Full Analysis

What is Sarepta Therapeutics Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

LTS:0L35 vs ABCL, RAPP, RXRX: Short Interest Comparison

For the Biotechnology subindustry, Sarepta Therapeutics's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Sarepta Therapeutics Short Interest vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sarepta Therapeutics's Short Interest distribution charts can be found below:

* The bar in red indicates where Sarepta Therapeutics's Short Interest falls into.


LTS:0L35
51GF Score
Sarepta Therapeutics Inc LTS:0L35
Short Interest is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Sarepta Therapeutics (LTS:0L35) Overvalued in 2026?

Based on GuruFocus' analysis, Sarepta Therapeutics stock appears to be undervalued. The current stock price of $16.10 is trading 87.4% below its estimated GF Value™ of $128.15. GuruFocus considers Sarepta Therapeutics to be Possible Value Trap.

Key valuation signals for LTS:0L35:

  • Short Interest:
  • GF Value™: $128.15 vs. price of $16.10 (87.4% below fair value)
  • GF Score™: 51/100 with 5 warning signs

No single metric tells the full story. See the LTS:0L35 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Sarepta Therapeutics Business Description

Address 215 First Street, Suite 415, Cambridge, MA, USA, 02142
Sarepta Therapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, gene therapies, and other genetic medicines for rare diseases, particularly neuromuscular disorders. The company has developed approved treatments for Duchenne muscular dystrophy, including EXONDYS 51, VYONDYS 53, AMONDYS 45, and ELEVIDYS, and is advancing additional therapeutic candidates for neuromuscular and other rare diseases. The company operates in one segment: discovering, developing, manufacturing, and delivering therapies to patients with rare diseases.
51GF Score

Get the complete analysis for LTS:0L35

Short Interest is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$16.10
Price
$128.15
GF Value